Results 11 to 20 of about 25,087 (209)

Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. [PDF]

Am J Hematol
American Journal of Hematology, Volume 101, Issue 3, Page 577-580, March 2026.
Konopleva M, DiNardo CD, Sun Y, Jung P, Loghavi S, Potluri J, Dail M, Chyla B, Pollyea DA.   +8 more
europepmc   +2 more sources

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

Scientific Reports, 2023
Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials ...
Lilly Velentza, Malin Wickström, Per Kogner, Claes Ohlsson, Farasat Zaman, Lars Sävendahl   +5 more
doaj   +1 more source

Targeting BCL-2 regulated apoptosis in cancer [PDF]

, 2018
The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death ...
Campbell, Kirsteen J., Tait, Stephen W.J.   +1 more
core   +1 more source

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]

, 2017
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2022
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL).
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach   +10 more
doaj   +1 more source

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia

Haematologica, 2023
CD40 signaling upregulates BCL-XL and MCL-1 expression in the chronic lymphocytic leukemia (CLL) lymph node microenvironment, affording resistance to the BCL-2 inhibitor, venetoclax.
Zhenghao Chen, Gaspard Cretenet, Valeria Carnazzo, Helga Simon-Molas, Arnon P. Kater, Gerritje J. W. van der Windt, Eric Eldering   +6 more
doaj   +1 more source

Constitutive IP₃ signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP₃ receptor disruptor BIRD-2 [PDF]

, 2018
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5 ...
Akl, Haidar, Baes, Myriam, Bittremieux, Mart, Bootman, Martin D., Bultynck, Geert, De Smedt, Humbert, Dubron, Kathia, Efremov, Dimitar G., Janssens, Ann, La Rovere, Rita M., Laurenti, Luca, Martines, Claudio, Mikoshiba, Katsuhiko, Morciano, Giampaolo, Parys, Jan B., Pinton, Paolo, Rietdorf, Katja, Vandenberghe, Peter, Welkenhuyzen, Kirsten   +18 more
core   +3 more sources

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Haematologica, 2022
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly ...
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro   +24 more
doaj   +1 more source

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT [PDF]

, 2017
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation ...
Beelen, Dietrich, Bittenbring, Jörg, Blaise, Didier, Blok, Henric-Jan, Castagna, Luca, Chevallier, Patrice, Ciceri, Fabio, Corradini, Paolo, Eikema, Dirk-Jan, Foá, Roberto, Hallek, Michael, Hilgendorf, Inken, Koc, Yener, Kröger, Nicolaus, Moreno, Carol, Müller, Lutz Peter, Schetelig, Johannes, Selleslag, Dominik, Solano, Carlos, Theobald, Matthias, Tischer, Johanna, van Gelder, Michel, van Gorkom, Gwendolyn, van Lint, M. T.   +23 more
core   +1 more source